Shamburg News · 8-K filed Nov 10, 2026, 8:15 AM EST

Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Update

ATOS · ATOSSA THERAPEUTICS, INC.

  • Earnings
  • Other event
  • Material agreement
  • Materiality: high

Atossa Therapeutics reported a net loss of $5.6 million, or $0.56 per share, for the third quarter ended September 30, 2026, compared with a net loss of $8.7 million, or $1.01 per share, a year earlier. Total operating expenses were $5.9 million for the quarter and $24.5 million for the nine months ended September 30, 2026. The company also disclosed a Stapled Contingent Value Rights Agreement entered October 8, 2026, under which holders share 25% of net proceeds from a future priority review voucher sale, capped at $50 million.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-454486.

Written from the filing by Shamburg Markets. Figures are as reported by the company.